Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AspiRe HCC Trial
NCT07529262Phase 3Not yet recruiting
- Sponsor
- Curtin University
- Start
- Jun 2026
- Primary completion
- Jun 2030
- Modality
- Orthosteric Ligands
01
Overview
A Phase 3 trial of aspirin in hepatocellular carcinoma (HCC), sponsored by Curtin University. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
aspirin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07529262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07529262.